Fig. 3.

Effects of tirabrutinib on mechanical properties of bone.

Bone loss was induced in C57BL/6N mice by intraperitoneally administering RANKL every 24 h for a total of 3 administrations. Tirabrutinib or tofacitinib at each dose was administered orally twice daily for a total of 5 administrations from day 0 to day 2. Anti-RANKL antibody was subcutaneously administered twice in total on day −7 and day −4. At 1.5 h following the final induction, blood was collected and the femur was excised. (a) For the distal end of the femur, the trabecular structure was analyzed by μCT to obtain 3-dimensional images. (b) Data are expressed as the mean ± standard error for 10 animals in each group.***: p < .001 vs Sham group. ###: p < .001 vs group with vehicle.